- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-04-01-2022
Seven Lessons I Learned Working at a Biotech Startup
April 11, 2022
Back Page
42
4
How early stage can help set you up for big stage.
Next-Gen Partnerships: The Ascent of Advanced Therapies
April 11, 2022
Features
42
4
With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.
Advantage Pharma: Capitalizing on Workforce Lessons
April 11, 2022
Features
42
4
With an increase in drug development, why purpose should be the pharma industry’s secret advantage in the global talent shortage, as the COVID-19 crisis transitions into the endemic stage.
Diversity in Action: Q&A With Reshma Kewalramani
April 11, 2022
Features
42
4
Reshma Kewalramani, MD, FASN, chief executive officer and president of Vertex Pharmaceuticals talks about how she supports the efforts of DE&I within and outside her organization.
Diversity in Action: Q&A With Bob McMahon
April 11, 2022
Features
42
4
Robert McMahon, former president of Merck US Human Health, shares some of the challenges leaders face when grappling with how to transform their organizations to embrace DE&I.
Women and Diversity in Industry C-Suites: New Scorecards Tell the Story
April 11, 2022
Features
42
4
Benchmark study across healthcare sectors measures progress in advancing women and people of color into top leadership roles.
A Dogged Devotion
April 11, 2022
Executive Profile
42
4
Saving and transforming as many patients’ lives as possible has been the driving force behind Beth Seidenberg’s audacious career, where she has excelled as a doctor, researcher, and venture capitalist.
Surviving Biotech’s Longest and Steepest Bear Market Ever
April 11, 2022
Finance
42
4
What will current stranglehold mean for industry down the line?
The Case for Elevating a Brand’s Price Proposition
April 11, 2022
Managed Markets
42
4
Tackling the subjective limits of value proposition.
The Impact of Hybrid Workplace Decisions On DE&I Dynamics
April 11, 2022
DE&I
42
4
Why their influence on employee representation matters for pharma.
One to Watch: China’s Cell and Gene Therapies Industry
April 11, 2022
APAC
42
4
Exploring the market’s emergence on the global stage.
Europe’s New HTA System Spurs More Debate, Concern
April 11, 2022
Europe Report
42
4
Fresh round of discussions around health technology assessment.
Pharmaceutical Executive, April 2022 Issue (PDF)
April 11, 2022
Issue PDF
42
4
Click the title above for a link to open the Pharmaceutical Executive April 2022 issue in an interactive PDF format.
No Half Measures: How Medical Affairs Can Maximize and Measure Value
March 25, 2022
Features
42
4
Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
FDA Maps Strategies to Advance Pharmaceutical Quality
March 22, 2022
Washington Report
42
4
Quality metrics, more domestic production aim to avoid supply disruptions and drug shortages.